Table 1 Baseline (pre-treatment) characteristics of trial participants for all 92 participants
PLA (N = 30) | LEV-3 (N = 33) | LEV-5 (N = 29) | |
|---|---|---|---|
Sex | |||
Female | 10 (33.3) | 10 (30.3) | 10 (34.5) |
Male | 20 (66.7) | 23 (69.7) | 19 (65.5) |
Age, mean ± SD | 50.1 ± 11.2 | 46.6 ± 13.1 | 47.0 ± 13.1 |
MFD, mf/mL | |||
Arithmetic mean ± SD | 24,796 ± 27,535 | 16,057 ± 13,168 | 20,594 ± 28,314 |
Minimum; maximum | 4240; 113,500 | 15; 48,935 | 0/400a; 130,230 |
Geometric mean (95% CI) | 16,268 (11,721–22,579) | 8883 (4974–15,863) | 11,607 (7311–18,426) |
Median [IQR] | 13,475 [7780–23,805] | 12,775 [5695–24,675] | 10,850 [6335–21,690] |
Mansonella perstans prevalence, N; % | 4; 13.1 | 1; 3.0 | 3; 10.3 |
Heart rate, mean (bpm) ± SD | 75 ± 13 | 79 ± 18 | 77 ± 12 |
Mean blood pressure, mean (mmHg) ± SD | 102 ± 15 | 102 ± 18 | 103 ± 16 |
Systolic blood pressure, mean (mmHg) ± SD | 138 ± 22 | 137 ± 21 | 139 ± 22 |
Diastolic blood pressure, mean (mmHg) ± SD | 84 ± 13 | 84 ± 17 | 85 ± 15 |
Body temperature, mean (°C) ± SD | 36.1 ± 0.4 | 36.2 ± 0.4 | 36.2 ± 0.5 |
